Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain
- PMID: 22898337
- PMCID: PMC3680944
- DOI: 10.1186/bcr3244
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain
Abstract
Introduction: We investigated the status of estrogen receptor alpha (ERα), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) in primary tumor and in the corresponding brain metastases in a consecutive series of breast cancer patients. Additionally, we studied factors potentially influencing conversion and evaluated its association with survival.
Methods: The study group included 120 breast cancer patients. ERα, PR, and HER2 status in primary tumors and in matched brain metastases was determined centrally by immunohistochemistry and/or fluorescence in situ hybridization.
Results: Using the Allred score of ≥ 3 as a threshold, conversion of ERα and PR in brain metastases occurred in 29% of cases for both receptors, mostly from positive to negative. Conversion of HER2 occurred in 14% of patients and was more balanced either way. Time to brain relapse and the use of chemotherapy or trastuzumab did not influence conversion, whereas endocrine therapy induced conversion of ERα (P = 0.021) and PR (P = 0.001), mainly towards their loss. Receptor conversion had no significant impact on survival.
Conclusions: Receptor conversion, particularly loss of hormone receptors, is a common event in brain metastases from breast cancer, and endocrine therapy may increase its incidence. Receptor conversion does not significantly affect survival.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3680944/bin/bcr3244-1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3680944/bin/bcr3244-2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3680944/bin/bcr3244-3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3680944/bin/bcr3244-4.gif)
Similar articles
-
Receptor conversion in distant breast cancer metastases.Breast Cancer Res. 2010;12(5):R75. doi: 10.1186/bcr2645. Epub 2010 Sep 23. Breast Cancer Res. 2010. PMID: 20863372 Free PMC article.
-
HER2 Receptor Conversion Is a strong Survival Predictor in Patients with Breast Cancer Brain Metastases.World Neurosurg. 2021 Aug;152:e332-e343. doi: 10.1016/j.wneu.2021.05.096. Epub 2021 May 29. World Neurosurg. 2021. PMID: 34062302
-
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.J Natl Cancer Inst. 2018 Jun 1;110(6):568-580. doi: 10.1093/jnci/djx273. J Natl Cancer Inst. 2018. PMID: 29315431
-
Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.Cancer Metastasis Rev. 2016 Sep;35(3):427-37. doi: 10.1007/s10555-016-9631-3. Cancer Metastasis Rev. 2016. PMID: 27405651 Review.
-
Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.Surg Today. 2020 Jul;50(7):657-663. doi: 10.1007/s00595-019-01831-8. Epub 2019 Jun 12. Surg Today. 2020. PMID: 31190183 Review.
Cited by
-
Brain Metastases from Breast Cancer Histologically Exhibit Solid Growth Pattern with at Least Focal Comedonecrosis: A Histopathologic Study on a Monocentric Series of 30 Cases.Diagnostics (Basel). 2023 Oct 6;13(19):3141. doi: 10.3390/diagnostics13193141. Diagnostics (Basel). 2023. PMID: 37835885 Free PMC article.
-
Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor.J Pathol Transl Med. 2023 Jul;57(4):217-231. doi: 10.4132/jptm.2023.06.10. Epub 2023 Jul 11. J Pathol Transl Med. 2023. PMID: 37460396 Free PMC article.
-
What if: A retrospective reconstruction of resection cavity stereotactic radiosurgery to mimic neoadjuvant stereotactic radiosurgery.Front Oncol. 2023 Mar 16;13:1056330. doi: 10.3389/fonc.2023.1056330. eCollection 2023. Front Oncol. 2023. PMID: 37007157 Free PMC article.
-
Neurosurgical Interventions for Cerebral Metastases of Solid Tumors.Dtsch Arztebl Int. 2023 Mar 10;120(10):162-169. doi: 10.3238/arztebl.m2022.0410. Dtsch Arztebl Int. 2023. PMID: 36650742 Free PMC article. Review.
-
The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine.Front Oncol. 2022 Dec 20;12:1014711. doi: 10.3389/fonc.2022.1014711. eCollection 2022. Front Oncol. 2022. PMID: 36605448 Free PMC article.
References
-
- Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A. International Breast Cancer Study Group (IBCSG): identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann Oncol. 2006;14:935–944. doi: 10.1093/annonc/mdl064. - DOI - PubMed
-
- Crivellari D, Pagani O, Veronesi A, Lombardi D, Nolè F, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A. International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol. 2001;14:353–356. doi: 10.1023/A:1011132609055. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous